S

Sanofi

Global pharma company; vaccines and R&D

Group Lead – Medical Information

Full-TimeDeadline 10/22/26
No salary listed
Expert
Bachelor's, Master's, PhD, MD
Hyderabad, Telangana, India
In Person
Content & WritingTechnical Writing

About the job

Requirements
  • At least 10 years of experience in content creation in medical information or scientific writing for the pharmaceuticals or healthcare industry, or equivalent experience in a clinical setting or pharmacovigilance.
  • At least 10 years of direct medical information writing experience in a pharmaceutical company.
  • At least 3 years of experience managing global, cross-functional teams and working in a matrix environment.
  • Strong ability to manage a multi-layered team of at least 10 members and influence and negotiate difficult situations.
  • Excellent written, verbal, and presentation communication skills; team and stakeholder management skills; ability to work independently and collaboratively; and demonstrated ability to motivate, coach, mentor, work as a subject matter expert, and develop and manage high-performing teams.
  • Expert knowledge of medical information documents, including response documents, compendia reviews, and FDA Annual Reports; medical operational excellence; time and risk management; medical editing and writing; literature evaluation; and multilevel response development.
  • Advanced degree in life sciences, pharmacy, or a similar discipline (Ph.D., master's, or bachelor's in science, or Doctor of Pharmacy), or a medical degree (MBBS, BDS, BAMS, BHMS, or MD).
  • Excellent spoken and written English.
  • Understanding of local country legal requirements for providing medical information documents to customers, including healthcare professionals, patients, carers, and other relevant decision makers.
Responsibilities
  • Act as a strategic thought partner to the Global Medical Information function, aligned with the vision of Medical Writing.
  • Conduct literature searches and reviews, and extract and summarize complex data from scientific literature.
  • Independently generate evidence-based, accurate, current, and fair-balanced data summaries for scientific response documents for products across multiple therapeutic areas; develop US FDA Annual Reports; and review compendia.
  • Produce medical documents in accordance with relevant global and country guidelines and policies.
  • Maintain subject matter expertise in processes, templates, guidelines, deliverables, and relevant industry trends and developments.
  • Provide operational and functional leadership to produce high-quality deliverables from the medical writing team.
  • Peer review, coach, mentor, and develop team expertise in deliverables, processes, templates, and guidelines.
  • Guide and oversee the end-to-end process captured in the activity catalogue.
  • Work in alignment with line-function visions and collaborate with the team.
  • Work across therapeutic areas and new deliverable types, and participate in cross-functional project teams as needed.
  • Complete assigned projects on schedule and collaborate with Global Medical Information teams to execute content plans.
  • Apply a deep understanding of, or experience working in, a regulated GxP environment.
  • Provide functional and operational direction across global business units, segments, key markets, therapeutic areas, and processes to optimize delivery and achieve cost savings.
  • Maintain effective relationships with medical scientific community stakeholders across global business units and products to develop medical information content as required.
  • Interact with stakeholders in medical and pharmacovigilance departments, and assist other medical information writers by developing knowledge and sharing expertise.
  • Provide coaching, mentoring, and expert support; oversee local and custom scientific response documents, US FDA Annual Reports, and compendia reviews to agreed timelines and quality standards.
  • Support project delivery in resourcing, quality, timeliness, efficiency, and technical standards; implement annual medical information writing plans and associated activities for assigned countries and regions.
  • Support quality enhancement by ensuring high scientific standards, compliance procedures, and internal and operational risk controls in accordance with applicable regulatory standards.
  • Work with selected regional vendors to deliver required deliverables in accordance with defined processes.
  • Develop action plans based on end-customer feedback and improve course content and delivery, continuous improvement, and efficiency.
  • Work with global medical teams and country, regional, and area teams to identify medical information needs and develop assigned deliverables.
  • Liaise with the Medical department to prepare customized deliverables; collaborate with Global and country Medical Information teams; and support regulatory interactions with health authorities for inspections.
Desired Qualifications
  • Understanding of local country legal requirements for medical information document provision, including the ABPI Code of Practice for the UK.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...